Agios Pharmaceuticals, Inc. (NASDAQ:AGIO – Get Free Report) saw a large increase in short interest during the month of December. As of December 15th, there was short interest totalling 5,120,000 shares, an increase of 12.0% from the November 30th total of 4,570,000 shares. Approximately 9.3% of the shares of the stock are sold short. Based on an average trading volume of 805,900 shares, the short-interest ratio is presently 6.4 days.
Agios Pharmaceuticals Price Performance
AGIO stock opened at $33.03 on Tuesday. The company has a market capitalization of $1.88 billion, a PE ratio of 2.91 and a beta of 0.80. Agios Pharmaceuticals has a 12 month low of $20.96 and a 12 month high of $62.58. The firm’s 50-day moving average is $48.89 and its 200 day moving average is $46.16.
Analysts Set New Price Targets
A number of equities research analysts recently commented on the company. Leerink Partners downgraded Agios Pharmaceuticals from an “outperform” rating to a “market perform” rating and decreased their target price for the stock from $60.00 to $56.00 in a research report on Friday, September 27th. Leerink Partnrs downgraded Agios Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Friday, September 27th. Royal Bank of Canada boosted their price target on shares of Agios Pharmaceuticals from $55.00 to $57.00 and gave the stock an “outperform” rating in a research report on Tuesday, December 10th. Raymond James reiterated an “outperform” rating and set a $51.00 price objective on shares of Agios Pharmaceuticals in a research report on Thursday, October 10th. Finally, Scotiabank upped their target price on shares of Agios Pharmaceuticals from $53.00 to $75.00 and gave the company a “sector outperform” rating in a research report on Monday, December 9th. Five research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat.com, Agios Pharmaceuticals has a consensus rating of “Hold” and an average price target of $56.33.
Institutional Trading of Agios Pharmaceuticals
A number of hedge funds have recently added to or reduced their stakes in AGIO. Caxton Associates LP grew its position in shares of Agios Pharmaceuticals by 0.7% in the 2nd quarter. Caxton Associates LP now owns 37,453 shares of the biopharmaceutical company’s stock worth $1,615,000 after buying an additional 264 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Agios Pharmaceuticals by 21.4% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,058 shares of the biopharmaceutical company’s stock worth $94,000 after purchasing an additional 363 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of Agios Pharmaceuticals by 6.0% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 12,132 shares of the biopharmaceutical company’s stock valued at $539,000 after purchasing an additional 688 shares during the last quarter. Acadian Asset Management LLC acquired a new stake in shares of Agios Pharmaceuticals in the 2nd quarter worth $37,000. Finally, Quest Partners LLC acquired a new position in Agios Pharmaceuticals during the 2nd quarter valued at about $40,000.
Agios Pharmaceuticals Company Profile
Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.
Featured Stories
- Five stocks we like better than Agios Pharmaceuticals
- Best Stocks Under $10.00
- 3 Must-Hold Stocks with Double-Digit Upside for 2025
- What Investors Need to Know to Beat the Market
- Micron: Why Now Is the Time to Be Brave
- Diversification Can Smooth Returns And Mitigate Portfolio Risk
- 3 Stocks That Wall Street Insiders Can’t Stop Buying
Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.